AIM ImmunoTech Inc. — Q1 2022 Form 10-Q
Business context and reporting period
The filing covers the three months ended March 31, 2022. AIM is a clinical-stage immunopharmaceutical company focused primarily on developing Ampligen (rintatolimod) for cancers, ME/CFS and viral conditions. Ampligen is not FDA-approved or marketed in the United States; it is approved for severe CFS in Argentina, where commercial distribution was still awaiting final product testing and regulatory release. Alferon N Injection is approved for certain uses, but production of new inventory was on hold.
Financial results and liquidity
Amounts below are in thousands of dollars, except per-share data.
| Metric | Q1 2022 | Q1 2021 |
|---|---|---|
| Revenue | $33 | $28 |
| Production costs | $77 | $237 |
| Research and development | $1,036 | $1,424 |
| General and administrative | $2,072 | $2,112 |
| Operating loss | $(3,152) | $(3,745) |
| Net loss | $(3,820) | $(3,579) |
| Basic and diluted loss per share | $(0.08) | $(0.08) |
| Cash used in operating activities | $(2,758) | $(3,045) |
- Cash and cash equivalents were $28.989 million and marketable securities were $15.554 million at quarter-end, totaling $44.543 million. This was down $3.725 million from $48.268 million at December 31, 2021.
- Total assets were $54.155 million; stockholders’ equity was $53.301 million. Current liabilities were $766,000. Long-term liabilities included $84,000 of operating lease obligations and $4,000 of redeemable warrants. The filing reports no material conventional borrowings at quarter-end.
- Net investing cash use was $346,000; financing cash flow was zero, compared with $12.794 million provided in Q1 2021, largely from stock issuance. Cash declined $3.104 million during Q1 2022.
- Gross margin is not a useful indicator here given the very small revenue base and the presentation of production costs separately from revenue.
Changes versus the prior comparable period
- Revenue rose $5,000, while operating loss narrowed by $593,000, mainly as R&D and production expenses decreased.
- Net loss increased $241,000, or about 7%, despite lower operating expenses. The principal unfavorable item was a $934,000 investment loss, mostly unrealized; this was partly offset by lower expenses and a $31,000 gain from warrant revaluation.
- R&D expense fell $388,000, mainly because certain clinical trials had ended and new trials had not yet begun. G&A decreased $40,000, including lower stock-based compensation, partly offset by higher professional, insurance and payroll costs.
- Operating cash use improved by $287,000. The quarter had no financing proceeds, unlike Q1 2021, when the company received $12.887 million net from stock sales.
Outlook, risks and notable items
- Management said existing funds were expected to cover anticipated operating needs and current clinical trials for approximately 24 months. It also warned that additional funding may be needed; the effective S-3 shelf registration could permit future capital raises, which may dilute shareholders.
- The FDA released the clinical hold on the planned Phase 2 pancreatic cancer study in March 2022. In April, after quarter-end, AIM signed a work order for trial management and estimated study cost at approximately $8.2 million, with an anticipated duration of 4.6 years. These are plans and estimates, not assured outcomes.
- A March 3, 2022 agreement provided for sale of the New Brunswick facility for $3.9 million, subject to the buyer’s mortgage contingency, then due to expire June 1; management anticipated a closing by July 1 if the condition was met. The property was classified as held for sale. The filing does not report a completed sale in the quarter.
- AIM expects to rely on contract manufacturers for future Ampligen active ingredient production. It said current supply should meet present needs, but manufacturing capacity, vendor arrangements and product availability remain risks. Alferon production and renewed U.S. sales depend on manufacturing arrangements and FDA approvals, with no definitive restart timetable.
- Key risks include clinical-trial failure or delay, regulatory requirements, limited commercial revenue, funding needs, manufacturing constraints, and the possibility that products may not gain market acceptance or generate meaningful sales. The company reported that disclosure controls were effective and that no material change in internal financial controls occurred during the quarter. It reported no new legal proceedings during the quarter.
Important facts for investors to verify
- Whether the facility sale closed, and the net proceeds and timing after satisfying the mortgage contingency.
- Whether the pancreatic cancer Phase 2 trial commenced as planned, its actual budget and funding requirements, and subsequent enrollment or regulatory developments.
- Cash burn and remaining liquidity relative to management’s approximately 24-month runway estimate, including any later capital raises or dilution.
- Progress toward Argentine commercial launch and FDA requirements for Ampligen and Alferon manufacturing, product release and sales.
- Whether clinical findings described by the company translate into controlled-trial evidence and regulatory approval; most discussed indications remain investigational.